# GLP-1 Semaglutide Dosage Chart: Clinical Guide

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/semaglutide-dosing-guide-clinical-chart-protocol/
> **Published:** 2026-06-05T18:13:04-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:05:28-04:00
> **Clinical Summary:** Explore the semaglutide dosing guide with clinical charts and protocols for diabetes and weight management. Understand titration and safety.

---

GLP-1 Clinical Relevance  #53Moderate Clinical Relevance  Relevant context for GLP-1 prescribers; interpret with care.
⚕ GLP-1 News  |  CED Clinic
Clinical GuideDosage ProtocolType 2 DiabetesSemaglutideEndocrinologyAdults with Metabolic DiseaseGlycemic ControlGLP-1 Receptor Agonism[Weight Management](https://cedclinic.com/cannabis-metabolism-weight-management-science/)OzempicWegovyInjection Administration

Why This Matters

Family medicine clinicians must understand semaglutide’s distinct dosing regimens across indications because Ozempic (diabetes) and Wegovy ([weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/)) have different maximum doses and titration schedules, with prescribing errors creating significant safety and efficacy risks. The multiple brand formulations and delivery routes require careful patient counseling to prevent medication errors, particularly when patients transition between indications or when insurance coverage drives substitution decisions. Accurate dosing knowledge directly impacts glycemic control in diabetic patients and weight loss outcomes in non-diabetic patients while minimizing adverse effects including GI symptoms and the rare but serious risk of thyroid C-cell tumors at high doses.

Clinical Summary

Semaglutide is a GLP-1 receptor agonist approved for two distinct clinical indications with separate dosing regimens. For type 2 diabetes management, semaglutide is available as a once-weekly subcutaneous injection (Ozempic) or oral formulation (Rybelsus), with the injectable form demonstrating superior glycemic control and demonstrating HbA1c reductions of 1.0 to 1.8 percentage points depending on dose and baseline characteristics. The subcutaneous formulation employs a titration schedule beginning at 0.25 mg weekly, increasing by 0.25 mg increments at four-week intervals, with a typical maintenance dose of 1 mg weekly and a maximum approved dose of 2 mg weekly. The oral formulation follows a different titration pattern, starting at 3 mg daily and titrating to 7 mg or 14 mg daily, and demonstrates approximately 0.8 to 1.3 percentage point HbA1c reductions.

For chronic [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) in non-diabetic individuals, semaglutide is marketed as Wegovy with a more aggressive titration protocol and higher target doses. The Wegovy regimen initiates at 0.25 mg weekly and escalates by 0.25 mg increments every week for four weeks, followed by 0.5 mg weekly maintenance in week five. Patients then advance to 1 mg, 1.7 mg, and finally 2.4 mg weekly at four-week intervals. [Clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) demonstrate mean weight loss of approximately 10 to 15 percent of baseline body weight with the 2.4 mg dose, with some patients achieving weight reductions exceeding 20 percent of initial weight.

Prescribers must recognize that gastrointestinal [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) constitute the primary tolerability concern with semaglutide across all formulations and indications. Nausea occurs in approximately 25 to 40 percent of patients, with incidence highest during titration phases and typically decreasing with continued use. Contraindications include personal or family history of medullary thyroid carcinoma

Clinical Takeaway

Semaglutide is a GLP-1 receptor agonist available in multiple formulations (Ozempic for diabetes, Wegovy for weight management, and Rybelsus oral tablet) that requires careful dose titration starting at 0.25 mg weekly and escalating based on tolerability and glycemic response. Standard maintenance dosing typically reaches 0.5 to 1 mg weekly for diabetes management and up to 2.4 mg weekly for weight loss, with dose escalation occurring every 4 weeks to minimize gastrointestinal [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/). Common adverse effects include nausea, vomiting, and constipation during titration, but these often resolve with slower dose advancement and [patient education](https://cedclinic.com/medical-cannabis-patient-education-basics/) on dietary modifications. When counseling patients, emphasize that this medication works best as part of a comprehensive lifestyle program, and set realistic expectations that dose titration requires patience over 16-20 weeks to reach therapeutic targets while monitoring for dehydration and acute kidney injury risk.

Dr. Caplan’s Take

“Semaglutide’s tiered dosing approach reflects the fundamental pharmacology of GLP-1 receptor agonists, where we titrate upward to optimize efficacy while minimizing gastrointestinal [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) that often drive patients to discontinuation. The distinction between Ozempic and Wegovy is crucial for [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) because they use identical active ingredients at different target doses, and I’ve found that clearly explaining this to patients reduces confusion about why their diabetes dosing differs from their weight management dosing. Understanding the specific dosing schedules and safety parameters isn’t just academic for us as prescribers; it’s the foundation for patient adherence and long-term metabolic benefit. When counseling patients, I emphasize that slower titration isn’t a limitation but rather our evidence-based strategy for tolerability and sustained use.”

Clinical Perspective
Semaglutide’s dual indication pathway (Ozempic for glycemic control versus Wegovy for weight management) requires clinicians to distinguish between diabetes-driven prescribing and metabolic weight loss optimization, as dosing schedules and patient selection criteria differ substantially between these FDA-approved indications. Within the current GLP-1 landscape characterized by supply constraints and prior authorization barriers, understanding the specific dosing trajectory for each indication prevents treatment delays and improves payer coverage outcomes. Concrete action: establish a standardized intake protocol that documents whether semaglutide is being prescribed for HbA1c reduction in established type 2 diabetes or for weight management in metabolically dysfunctional patients, then align initial dosing and titration schedules accordingly before submitting prescriptions.

💬 Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/)

Have thoughts on this? Share it:

[𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20%3Cb%3Esemaglutide%3C%2Fb%3E%20dosage%20chart%20-%20dosing%20guide%20and%20safety%20tips%20%28a8erogtu%29%20%40drcaplan&url=https%3A%2F%2Fethnobotanyjournal.org%2Fplugins%2Fgeneric%2FpdfJsViewer%2Fpdf.js%2Fweb%2Fviewer.html%3Ffile%3D%252Findex%252Ephp%252Findex%252Flogin%252FsignOut%253Fsource%253D.ojsnua44.top%26vid%3D5ubrwDk7nl)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fethnobotanyjournal.org%2Fplugins%2Fgeneric%2FpdfJsViewer%2Fpdf.js%2Fweb%2Fviewer.html%3Ffile%3D%252Findex%252Ephp%252Findex%252Flogin%252FsignOut%253Fsource%253D.ojsnua44.top%26vid%3D5ubrwDk7nl)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20%3Cb%3Esemaglutide%3C%2Fb%3E%20dosage%20chart%20-%20dosing%20guide%20and%20safety%20tips%20%28a8erogtu%29%20--%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fethnobotanyjournal.org%2Fplugins%2Fgeneric%2FpdfJsViewer%2Fpdf.js%2Fweb%2Fviewer.html%3Ffile%3D%252Findex%252Ephp%252Findex%252Flogin%252FsignOut%253Fsource%253D.ojsnua44.top%26vid%3D5ubrwDk7nl)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/)

📰 Source: [Google Alert – (Ozempic OR Wegovy OR Mounjaro OR Zepbound OR semaglutide OR tirzepatide OR liraglutide)](https://ethnobotanyjournal.org/plugins/generic/pdfJsViewer/pdf.js/web/viewer.html?file=%2Findex%2Ephp%2Findex%2Flogin%2FsignOut%3Fsource%3D.ojsnua44.top&vid=5ubrwDk7nl)

Nationwide GLP-1 Care
Looking for thoughtful, physician-led GLP-1 guidance?

 CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care.
 

[Learn More](https://cedclinic.com/metabolic/)
[Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services)

Table of Contents

- [FAQ](#FAQ)[What is semaglutide and what is it used for?](#What_is_semaglutide_and_what_is_it_used_for)
- [What are the different brand names for semaglutide?](#What_are_the_different_brand_names_for_semaglutide)
- [How does semaglutide work in my body?](#How_does_semaglutide_work_in_my_body)
- [Will semaglutide work for both diabetes and weight loss?](#Will_semaglutide_work_for_both_diabetes_and_weight_loss)
- [What dosage will I start on?](#What_dosage_will_I_start_on)
- [Are there safety concerns I should know about semaglutide?](#Are_there_safety_concerns_I_should_know_about_semaglutide)
- [How often do I take semaglutide?](#How_often_do_I_take_semaglutide)
- [What should I do if I miss a dose of semaglutide?](#What_should_I_do_if_I_miss_a_dose_of_semaglutide)
- [Can I stop taking semaglutide whenever I want?](#Can_I_stop_taking_semaglutide_whenever_I_want)
- [What common side effects might I experience?](#What_common_side_effects_might_I_experience)
- [Related](#Related)

## FAQ

#### What is semaglutide and what is it used for?

Semaglutide is a medication called a GLP-1 receptor agonist that helps lower blood sugar in type 2 diabetes and reduces appetite for weight management. It is sold under different brand names including Ozempic for diabetes, Wegovy for weight loss, and Rybelsus as an oral tablet form.

#### What are the different brand names for semaglutide?

Semaglutide is available as Ozempic for type 2 diabetes treatment, Wegovy for chronic weight management, and Rybelsus which is an oral tablet version. Each brand name targets a specific condition, but they all contain the same active ingredient.

#### How does semaglutide work in my body?

Semaglutide mimics a natural hormone called GLP-1 that helps regulate blood sugar levels and appetite signals in your brain. This helps you feel fuller longer and improves how your body controls blood glucose.

#### Will semaglutide work for both diabetes and weight loss?

Semaglutide can treat type 2 diabetes and aid weight loss, but the dosing and brand name differ between uses. Your doctor will prescribe the appropriate version based on whether you need diabetes management, weight management, or both.

#### What dosage will I start on?

Your doctor will start you on a low dose and gradually increase it over several weeks to help your body adjust and minimize side effects. The specific starting dose depends on which semaglutide product you are using and your individual health situation.

#### Are there safety concerns I should know about semaglutide?

Semaglutide is generally safe when prescribed appropriately, but like all medications it can cause side effects and may not be suitable for certain medical conditions. Your doctor will review your medical history and monitor you regularly to ensure safe use.

#### How often do I take semaglutide?

Most semaglutide injections are given once per week, making it convenient for regular use at home. Rybelsus, the oral tablet form, is taken once daily before breakfast.

#### What should I do if I miss a dose of semaglutide?

If you miss a weekly injection, take it as soon as you remember unless your next dose is within 2 days. Then resume your regular weekly schedule from that point without doubling up on doses.

#### Can I stop taking semaglutide whenever I want?

You should not stop semaglutide suddenly without talking to your doctor first. Stopping abruptly may cause your blood sugar to rise or weight to return, so your doctor will help you adjust your treatment plan if needed.

#### What common side effects might I experience?

Many patients experience mild nausea, especially when starting semaglutide, along with occasional vomiting or constipation that typically improve over time. If side effects persist or worsen, contact your doctor to discuss whether your dose needs adjustment.

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

[Leave a Message](https://cedclinic.com/contact/)
[Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
[Medical Consulting](https://cedclinic.com/book/)
[Cannabis Care](https://cedclinic.com/book/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

RELATED READING AT CED CLINIC

Continue exploring the evidence

[Semaglutide Weight Management: Clinical Evidence & Safety](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/)

Review clinical evidence and safety data for semaglutide in weight management to complement dosing knowledge.

[Read More](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/)

[GLP-1 Receptor Agonist Clinical Evidence: Liraglutide vs Semaglutide](https://cedclinic.com/semaglutide-vs-liraglutide-clinical-evidence/)

Compare clinical outcomes and dosing considerations between liraglutide and semaglutide GLP-1 receptor agonists.

[Explore Details](https://cedclinic.com/semaglutide-vs-liraglutide-clinical-evidence/)

[GLP-1 Weight Loss: Clinical Evidence and Outcomes](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/)

Understand the clinical outcomes of GLP-1 therapies for weight loss, supporting informed dosing decisions.

[Learn More](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).